Tesamorelin (10mg)
$150.00
- Sequence (single letter)
- Unk-Tyr-Ala-Asp-Ala-lle-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-lle-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu
- Molecular Formula
- C223H370N72O69S
- Molecular Weight
- 5195.908 g/mol
- PubChem CID
- 44147413
- CAS Number
- 901758-09-6
For laboratory research use only. Not for human use.
- Lyophilized peptides should be reconstituted using proper aseptic laboratory technique.
- Reconstitution must be performed using Canlab-supplied Bacteriostatic Water and handled in accordance with generally accepted research practices.
- Warranty related to reconstitution, sterility or material integrity applies only when Canlab Bacteriostatic Water is used.
- Use of third-party diluents or deviation from the provided handling guidance voids any applicable warranty.
For full handling instructions and limitations, see the Peptide Reconstitution, Research Use Only section in our Product Warranty Policy Page →
Description
Tesamorelin, an analogue of growth hormone releasing hormone (GHRH), mirrors the structure of standard GHRH, enhanced by the addition of an extra trans-3-hexanoic acid group. Developed by Theratechnologies in Canada, Tesamorelin earned FDA approval in 2010 as the latest drug for managing HIV-associated lipodystrophy. Beyond its approved use, the peptide has undergone exploration regarding its potential to enhance peripheral nerve regeneration and as a potential intervention for mild cognitive impairment (MCI), which precedes dementia.
Additional Information
Benefits
Please review the complete product description and available supporting documentation for product-specific research information. This product is sold strictly for laboratory research use.
Mechanism of Action
Refer to the product description, certificate of analysis and applicable published research for product-specific information. No medical or therapeutic claims are made.
